Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

被引：1
|
作者：
Schuler, M. [1 ]
Yang, J. [2 ,3 ]
Sequist, L. V. [4 ,5 ]
Yamamoto, N. [6 ]
Zhou, C. [7 ]
O'Byrne, K. [8 ,9 ]
Hirsh, V. [10 ]
Mok, T. [11 ]
Shah, R. [12 ]
Wu, Y. -L. [13 ,14 ]
机构：
[1] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Natl Taiwan Univ, Taipei, Taiwan
[4] Massachusetts Gen Hosp, Dept Thorac Oncol, Boston, MA 02114 USA
[5] Harvard Med Sch, Boston, MA USA
[6] Wakayama Med Univ, Dept Internal Med 3, Wakayama, Japan
[7] Tongji Univ, Shanghai Pulm Hosp, Shanghai, Peoples R China
[8] Princess Alexandra Hosp, Translat Res Inst, Brisbane, Qld, Australia
[9] Queensland Univ Technol, Brisbane, Qld, Australia
[10] McGill Univ, Dept Oncol, Montreal, PQ, Canada
[11] Chinese Univ Hong Kong, Hong Kong Canc Inst, State Key Lab South China, Hong Kong, Hong Kong, Peoples R China
[12] Maidstone Hlth Author, Kent Oncol Ctr, Maidstone, Kent, England
[13] Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China
[14] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(16)30248-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
138PD
引用
收藏
页码：S116 / S117
页数：2
相关论文
共 50 条
  • [1] Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥ 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    Wu, Y. -L.
    Sequist, L. V.
    Geater, S. L.
    Orlov, S.
    Lee, K. H.
    Tsai, C. -M.
    Kato, T.
    Kiura, K.
    Barrios, C. H.
    Schuler, M.
    Hirsh, V.
    Yamamoto, N.
    O'Byrne, K.
    Mok, T.
    Massey, D.
    Maerten, A.
    Yang, J. C. -H.
    ANNALS OF ONCOLOGY, 2015, 26 : 136 - 137
  • [2] Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6
    Barrios, Carlos H.
    Wu, Yi-Long
    Yang, James Chih-Hsin
    Sequist, Lecia V.
    Geater, Sarayut L.
    Mok, Tony
    Hu, Cheng-Ping
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Lu, Shun
    Hirsh, Vera
    Sebastian, Martin
    Okamoto, Isamu
    Shah, Riyaz
    Maerten, Angela
    Massey, Dan
    Wind, Sven
    Schuler, Martin
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S210 - S211
  • [3] Overall survival (OS) with afatinib (A) vs chemotherapy (CT) in patients (pts) with NSCLC harboring EGFR mutations (mut): Subgroup analyses by race in LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    Wu, Y. -L.
    Sequist, L. V.
    Schuler, M.
    Yamamoto, N.
    Zhou, C.
    Hu, C. -P.
    O'Byrne, K.
    Hirsh, V.
    Mok, T.
    Zazulina, V.
    Yang, J. C. -H.
    ANNALS OF ONCOLOGY, 2015, 26 : 136 - 136
  • [4] Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
    Yang, James C-H
    Sequist, Lecia V.
    Geater, Sarayut Lucien
    Tsai, Chun-Ming
    Mok, Tony Shu Kam
    Schuler, Martin
    Yamamoto, Nobuyuki
    Yu, Chong-Jen
    Ou, Sai-Hong I.
    Zhou, Caicun
    Massey, Daniel
    Zazulina, Victoria
    Wu, Yi-Long
    LANCET ONCOLOGY, 2015, 16 (07): : 830 - 838
  • [5] Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut): Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
    Sequist, L.
    Wu, Y.
    Schuler, M.
    O'Byrne, K.
    Sebastian, M.
    Popat, S.
    Boyer, M.
    Mok, T.
    Yamamoto, N.
    Hirsh, V.
    Geater, S. L.
    Zhou, C.
    Massey, D.
    Zazulina, V.
    Jones, H.
    Yang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S5 - S6
  • [6] Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials
    Wu, Yi-Long
    Sequist, Lecia V.
    Tan, Eng-Huat
    Geater, Sarayut L.
    Orlov, Sergey
    Zhang, Li
    Lee, Ki Hyeong
    Tsai, Chun-Ming
    Kato, Terufumi
    Barrios, Carlos H.
    Schuler, Martin
    Hirsh, Vera
    Yamamoto, Nobuyuki
    O'Byrne, Kenneth
    Boyer, Michael
    Mok, Tony
    Peil, Barbara
    Marten, Angela
    Yang, James Chih-Hsin
    Paz-Ares, Luis
    Park, Keunchil
    CLINICAL LUNG CANCER, 2018, 19 (04) : E465 - E479
  • [7] Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials
    Yang, J. C. -H.
    Sequist, L. V.
    Zhou, C.
    Schuler, M.
    Geater, S. L.
    Mok, T.
    Hu, C. -P.
    Yamamoto, N.
    Feng, J.
    O'Byrne, K.
    Lu, S.
    Hirsh, V.
    Huang, Y.
    Sebastian, M.
    Okamoto, I.
    Dickgreber, N.
    Shah, R.
    Maerten, A.
    Massey, D.
    Wind, S.
    Wu, Y. -L.
    ANNALS OF ONCOLOGY, 2016, 27 (11) : 2103 - 2110
  • [8] Overall Survival (OS) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common Epidermal Growth Factor Receptor Mutations (EGFR M+): Pooled Analysis of Two Large Phase III Studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) Comparing Afatinib With Chemotherapy (CT)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (10) : 7 - 9
  • [9] Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm plus ) NSCLC in LUX-Lung (LL) 3, 6 and 7
    Sequist, L.
    Wu, Y-L.
    Schuler, M.
    Kato, T.
    Yang, J. C-H.
    Tanaka, H.
    Hida, T.
    Lu, S.
    Park, K.
    Laurie, S.
    Bennouna, J.
    Sibilot, D. Moro
    Maerten, A.
    Peil, B.
    Ehrnrooth, E.
    Yamamoto, N.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials
    Passaro, Antonio
    Gori, Bruno
    de Marinis, Filippo
    JOURNAL OF THORACIC DISEASE, 2013, 5 (04) : 383 - 384
12345